Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | BUB1 | O43683 | 3/20 | 0.41 |
| ▸ | JAK2 | O60674 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766528 | 0.92 | PRKDC (0.52) | PRKDCBRAFBUB1NPC1RAB9A | |
| SCHEMBL3756839 | 0.91 | JAK2 (0.45) | PRKDCLRRK2BUB1JAK2PIK3CA | |
| SCHEMBL3761577 | 0.91 | PRKDC (0.42) | PRKDCBUB1NPC1RAB9APIK3CA | |
| SCHEMBL3759356 | 0.89 | GAK (0.38) | PRKDCBUB1JAK2NPC1RAB9A | |
| SCHEMBL3762759 | 0.88 | PRKDC (0.40) | PRKDCBUB1NPC1RAB9APIK3CA | |
| SCHEMBL3764901 | 0.88 | PIK3CA (0.41) | BRAFLRRK2BUB1JAK2NPC1 | |
| SCHEMBL3762181 | 0.87 | PIK3R1 (0.37) | LRRK2BUB1JAK2NPC1RAB9A | |
| SCHEMBL3760897 | 0.87 | STK4 (0.43) | PRKDCLRRK2BUB1PIK3CAATR | |
| SCHEMBL3761533 | 0.87 | KDM1A (0.40) | BUB1JAK2PIK3CAMTOR | |
| SCHEMBL3760222 | 0.87 | PIK3CA (0.45) | PRKDCBUB1PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | PRKDC 112/4885BRAF 20/4885LRRK2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.